Sermorelin (20 mg Vial) Dosage Protocol

Dosing & Reconstitution Overview

Sermorelin is a synthetic 29-amino-acid fragment of growth-hormone-releasing hormone (GHRH 1–29) studied for its ability to prompt the pituitary to secrete its own growth hormone. The figures below are compiled strictly for laboratory and educational reference — they describe how the compound was handled and dosed across published research, not a recommendation for use in humans or animals.

For a 20 mg vial, adding 4.0 mL of bacteriostatic water yields a concentration of 5 mg/mL (5,000 mcg/mL). At that concentration, every 0.02 mL drawn on a U-100 insulin syringe equals 2 units and delivers 100 mcg of material, so each single unit corresponds to 50 mcg — which keeps the arithmetic clean across the low-microgram titration steps typical of this compound.

Standard (Gradual) Titration Schedule

The gradual schedule mirrors the slow nightly dose-escalation seen in the research literature, where the amount is stepped up by roughly 100 mcg every one to two weeks to track tolerability and IGF-1 response before advancing.

Reconstitution Steps

1. Let the sealed lyophilized vial and the bacteriostatic water reach room temperature, then wipe both stoppers with an alcohol swab.
2. Draw 4.0 mL of bacteriostatic water and inject it slowly down the inside wall of the vial — never directly onto the powder pellet.
3. Swirl gently until fully dissolved. Do not shake; vigorous agitation can shear the peptide.
4. The solution should be clear and colourless. Label the vial with the concentration (5 mg/mL) and the reconstitution date.
5. Store upright under refrigeration between uses and draw subsequent volumes with a fresh sterile syringe each time.

Advanced (Aggressive) Titration Schedule

The advanced schedule reaches the upper 500 mcg nightly ceiling more quickly, holding each step for only one week. Even at the top dose the per-injection volume stays well within a single 0.3 mL syringe, so no multi-vial draw is ever required.

Supplies Needed

• Sermorelin vials (20 mg): a single vial covers an 8-week gradual run plus margin (~40 doses at the top step); keep one backup on hand for a 12-week schedule.
• Insulin syringes (U-100, 0.3 mL, 29–31G): one fresh syringe per nightly draw — roughly 56 for an 8-week run, 84 for 12 weeks.
• Bacteriostatic water (10 mL): one bottle reconstitutes two 20 mg vials with room to spare.
• Alcohol swabs: two per night (stopper plus site); a single 100-count box covers an 8-week schedule, two boxes for 12 weeks.
• Sharps container: one puncture-proof container sized for 56+ syringes.

Protocol Overview

• Research goal: model endogenous, pulsatile GH release and downstream IGF-1 support via GHRH-receptor stimulation.
• Schedule: once-daily subcutaneous administration at bedtime in the published model, typically across a 3–6 month window.
• Dose band: 200–500 mcg nightly (adult off-label); pediatric reference ~30 mcg/kg nightly.
• Fill: 20 mg lyophilized, reconstituted to 5 mg/mL with 4 mL diluent.
• Storage: 2–8 °C sealed; 2–8 °C once reconstituted, no freezing.

Dosing Protocol Notes

• Begin at the lowest 200 mcg step and raise by roughly 100 mcg every one to two weeks as tolerability allows.
• Administer once daily, ideally before sleep, to align with the natural nocturnal GH pulse.
• Target the 300–500 mcg band by weeks 5–8, adjusting against IGF-1 readings.
• Keep a fixed nightly cadence and rotate the sampling/handling site systematically.
• Track IGF-1 at baseline and every one to two months; long-term work should also watch thyroid status, since subclinical hypothyroidism can blunt the response.

Storage Instructions

Keep sealed lyophilized vials refrigerated at 2–8 °C (36–46 °F), protected from light and kept dry — do not freeze the powder. Once reconstituted with bacteriostatic water, store the solution at 2–8 °C and use it within about 10–14 days as a multi-dose vial. Avoid freezing the mixed solution, let refrigerated material warm slightly before drawing, and inspect each time to confirm it remains clear and colourless.

Important Handling Notes

• Use a sterile syringe for every draw and never re-enter the vial with a used needle.
• Swab the stopper with alcohol before each draw and let it dry.
• Document each draw — date, volume, remaining material — for reproducibility.
• Discard the reconstituted vial once past its 10–14 day window even if material remains.

How Sermorelin Works

Sermorelin is a truncated analog of growth-hormone-releasing hormone that binds GHRH receptors on the pituitary somatotropes, prompting them to release the body's own growth hormone in its natural pulsatile pattern. Because it works upstream rather than supplying GH directly, the resulting secretion stays subject to the normal negative-feedback governors — somatostatin and circulating IGF-1 — which limits the risk of supraphysiologic spikes. That pulsatile GH output in turn drives hepatic and peripheral IGF-1 production, the pathway linked to protein synthesis, lipolysis and tissue repair. Its action depends on a functional pituitary, distinguishing it from exogenous GH replacement.

Reported Benefits & Side Effects

Benefits observed in research

• Stimulation of endogenous pulsatile GH release with corresponding IGF-1 elevation.
• In pediatric GH deficiency, meaningful gains in height velocity and growth parameters over 6–12 month courses.
• In adult off-label contexts, modest reported shifts in body composition, recovery and metabolic markers — evidence is limited and effects are smaller than direct GH.
• Preservation of physiologic feedback, lowering the risk of excessive GH/IGF-1 versus exogenous hormone.

Side effects reported

• Injection-site reactions are the most common — transient redness, pain or swelling, around 17% incidence in trials.
• Rare systemic effects (under 1%): headache, flushing, dizziness, hyperactivity, drowsiness or hives.
• One study noted subclinical hypothyroidism in roughly 6.5% of subjects; untreated low thyroid blunts the GH response.
• No serious acromegaly, hypoglycemia or runaway IGF-1 elevations were reported at the studied doses, owing to intact feedback.

Supporting Lifestyle Factors (Research Context)

• Seven to nine hours of nightly sleep to align with and reinforce the natural GH pulse.
• Protein-forward nutrition (~1.6–2.2 g/kg/day) while avoiding heavy carbohydrate loads right before bed, which can blunt GH release.
• Resistance training several times weekly plus moderate aerobic activity to amplify the GH/IGF-1 signal.
• Stress control, since chronically elevated cortisol suppresses GH; alcohol and smoking similarly dampen the response.

Injection Technique (Reference Only)

• Prepare the vial and a subcutaneous site (abdomen at least two inches from the navel, outer thigh, upper outer arm) with alcohol swabs and let them dry.
• Insert subcutaneously at a 45–90° angle depending on needle length; aspiration is not required for subcutaneous work.
• Depress the plunger slowly, pause a moment, then withdraw at the same angle and apply gentle pressure without rubbing.
• Rotate sites systematically, keeping each at least one to two inches apart, and dispose of sharps in an approved container without recapping.

References

Related Protocols